JB Capital LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

JB Capital LLC lowered its position in Pfizer Inc. (NYSE:PFE) by 3.5% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 172,033 shares of the biopharmaceutical company’s stock after selling 6,314 shares during the period. JB Capital LLC’s holdings in Pfizer were worth $4,979,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Olistico Wealth LLC purchased a new position in shares of Pfizer in the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the 2nd quarter valued at about $29,000. Quarry LP acquired a new stake in Pfizer in the 2nd quarter valued at about $31,000. Financial Connections Group Inc. purchased a new position in Pfizer in the 2nd quarter worth approximately $34,000. Finally, ESL Trust Services LLC acquired a new position in shares of Pfizer during the 1st quarter worth approximately $37,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Barclays increased their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Sanford C. Bernstein initiated coverage on shares of Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Insider Activity

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Trading Up 0.3 %

NYSE PFE traded up $0.09 during trading on Thursday, hitting $27.45. The stock had a trading volume of 5,744,346 shares, compared to its average volume of 37,300,742. The firm has a 50 day moving average price of $28.96 and a 200 day moving average price of $28.64. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $31.54. The company has a market capitalization of $155.55 billion, a PE ratio of 36.96, a PEG ratio of 0.88 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.17) EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.12%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.